Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 2009

View Archived Issues

Recombinant T-cell receptor ligand RTL-551 reduces stroke lesion size in vivo

Unique androgen receptor antagonists identified at Duke University Medical Center

Phase I/II studies show low systemic absorption of dapivirine vaginal gel

Novartis has disclosed novel ALK inhibitors for obstructive airways diseases

TRPA1 antagonists claimed as analgesics by Abbott

Exelixis reports creation of protein kinase inhibitors as anticancer agents

Monoamine oxidase inhibitors developed as antibacterials at Ferrer

GSK describes novel mGlu5 receptor antagonists for substance abuse

Novel hypoxia-inducible factor inhibitors reported by FibroGen

Novo Nordisk presents results for second quarter 2009

New Levitra formulation submitted for registration in E.U.

Resolvyx presents data from phase II trial of RX-10045 in dry eye syndrome

Intercept Blood System for platelets receives Swiss approval

Liverpool School of Tropical Medicine leads antimalarial drug research project

Bavarian Nordic enters negotiations with U.S. authorities for Imvamune

MF-482 developed as a second-generation EP4 antagonist for treating inflammatory pain

Takeda describes preclinical profile of GnRH antagonist TAK-385

Abbott presents PAMs that target the alpha7 nicotinic acetylcholine receptor

Seattle Genetics completes enrollment in pivitol brentuximab vedotin trial

Three phase II studies of H1N1 influenza vaccine CSL-425 planned or under way

Santaris forms strategic alliance with Shire to develop RNA-based medicines

Valeant reports preliminary results of phase IIa retigabine study in PHN

Xyzal approved for use in young children

Ligand to acquire Neurogen

BioCancell's ovarian cancer drug granted orphan drug status in U.S.

Gloucester to meet with FDA Advisory Committee to discuss romidepsin NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...